Undisclosed Novel Antibiotic Program(s)
Infections caused by multi-drug-resistant bacteria
Key Facts
About smartbax
smartbax is a private, preclinical-stage biotech company tackling the global antimicrobial resistance (AMR) crisis through novel antibiotic discovery. The company's strategy focuses on inhibiting hydrolytic processes and targeting novel protein targets outside classical pathways to overcome bacterial resistance mechanisms. Founded by a scientifically strong team, including a CEO with a PhD in biochemistry and direct experience in novel antibiotic mechanisms, smartbax is building a platform that integrates medicinal chemistry, microbiology, and computational modeling. While still in the research and discovery phase, the company is positioned in a critical and high-need therapeutic area with significant market urgency.
View full company profile